Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. (A) Architecture of Doc2Hpo. (B) Interactive user interface

Published byHadian Sudjarwadi Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. (A) Architecture of Doc2Hpo. (B) Interactive user interface"— Presentation transcript:

1 Figure 1. (A) Architecture of Doc2Hpo. (B) Interactive user interface
Figure 1. (A) Architecture of Doc2Hpo. (B) Interactive user interface. 1. Automated extraction includes three parts: ... Figure 1. (A) Architecture of Doc2Hpo. (B) Interactive user interface. 1. Automated extraction includes three parts: light green highlights the clinical entity identified within the text, the term in the appended dark green box identifies the standardized HPO concept, and the ‘N’ button appended indicates the negation modifier (red for negation). 2–3. The user can highlight any text and add an HPO concept. The user can also double click to delete an erroneous extraction; 4–5. The user can change the standardized HPO concept by clicking the dark green box. The user could search for the desired HPO concept and make updates in real-time. 6. The user can click the ‘N’ button to change the negation modifier. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz386, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2. (A) Box and whisker plots of time consumption by using Doc2Hpo and manual curation across three different ... Figure 2. (A) Box and whisker plots of time consumption by using Doc2Hpo and manual curation across three different annotators. (B) The accuracy (precision, recall, and F1 score) for different approaches across different annotators. The error bars indicate the 95% confidence intervals. ‘Auto’ refers to fully automated HPO curation based on MetaMap without negation detection. ‘Auto (negex)’ refers to fully automated HPO curation based on MetaMap with negation detection. ‘Doc2hpo’ refers to Doc2Hpo-aided user curation. ‘Manual’ refers to user curation without using Doc2Hpo. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz386, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. (A) Architecture of Doc2Hpo. (B) Interactive user interface"

Similar presentations

J Exp Bot. 2017;68(17): doi: /jxb/erx352

J Exp Bot. 2017;68(17): doi: /jxb/erx352
From: Introducing the PRIDE Archive RESTful web services

From: Introducing the PRIDE Archive RESTful web services
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. (A) The VEGF promoter PQS and scheme of G oxidation to OG, as well as (B) the proposed APE1-dependent pathway ... Figure 1. (A) The VEGF promoter.

Figure 1. (A) The VEGF promoter PQS and scheme of G oxidation to OG, as well as (B) the proposed APE1-dependent pathway ... Figure 1. (A) The VEGF promoter.
Figure 1. Sgs1 binds to RPA-coated ssDNA

Figure 1. Sgs1 binds to RPA-coated ssDNA
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
Figure 1. An example of a thioviridamide-like molecule, thioalbamide, and inset, a proposed biochemical route to ... Figure 1. An example of a thioviridamide-like.

Figure 1. An example of a thioviridamide-like molecule, thioalbamide, and inset, a proposed biochemical route to ... Figure 1. An example of a thioviridamide-like.
Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.
Figure 1 The study area within Vienna Zoo is outlined in red

Figure 1 The study area within Vienna Zoo is outlined in red
Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing.

Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1. Aminoacylation of 3′-NH2-tRNA catalyzed by flexizymes

Figure 1. Aminoacylation of 3′-NH2-tRNA catalyzed by flexizymes
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
Figure 1. Position and number of NLS improves genome editing by AsCas12a, LbCas12a and FnoCas12a. (A) General schematic ... Figure 1. Position and number.

Figure 1. Position and number of NLS improves genome editing by AsCas12a, LbCas12a and FnoCas12a. (A) General schematic ... Figure 1. Position and number.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
Figure 1. Schematic illustration of CSN and NDM construction and our statistic model. (A) CSN and NDM construction. (i) ... Figure 1. Schematic illustration.

Figure 1. Schematic illustration of CSN and NDM construction and our statistic model. (A) CSN and NDM construction. (i) ... Figure 1. Schematic illustration.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion

Similar presentations

Ads by Google